Search

The new drug will target superbug like Methicillin resistant Staphylococcus aureus [ABSTRACT FROM AUTHOR]

The new drug will target superbug like Methicillin resistant Staphylococcus aureus [ABSTRACT FROM AUTHOR]

The article focuses on the need of a new antibacterial drug to treat the emerging multiple-drug resistance (MDR) gram-negative organisms. It is stated that the antibacterials available are only targeting gram-positive organism such as the methicillin resistant staphylococcus aureus (MRSA). Although new drugs are still for gram-positive organism, there is a significant opportunity that these drugs can treat MDR gram-negative organisms.

The article reports that the company Novoxel has presented data showing that the drug NXL101 destroys potentially problematic strains of Methicillin Resistant Staphylococcus Aureus (MRSA). The drug is manufactured by the company. The data was presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) that was held in Munich, Germany. The drug offers an alternative treatment option in the case of fluoroquinolone resistance.

The article presents news related to biotechnological drug application. Elan Corp. PLC and Biogen Idec Inc. may submit a supplemental biologics license application for Tyansabri drug from the United States Food and Drug Administration (FDA) for the treatment of multiple sclerosis. Dendreon Corp. plans to submit a marketing application to the FDA for Provenge drug. Cubist Pharmaceuticals Inc. seeks approval for a new indication for its antibiotic Cubicin at 6mg/kg for the treatment patients with a blood infection caused by Staphylococcus aureus.

The article reports that the Food and Drug Administration (FDA) of the United States has granted Cubist Pharmaceutical Inc.'s Cubicin priority review status in acute bacteremia and endocarditis. Cubicin, Cubist's only approved product so far, was initially launched in the U.S. market in November 2003. The drug, a cyclic lipopetide belonging to a new class of antibacterials is approved for the treatment of skin and skin-structure infections. Cubist Pharmaceuticals' Cubicin has been granted priority review status by the FDA for an additional indication in patients with bacteremia with known or suspected endocarditis caused by Staphylococcus aureus.

This article reports that a priority review status has been granted to Cubist Pharmaceuticals Inc.'s Cubicin by the U.S. Food and Development Administration for an additional indication in patients with bacteremia with known or suspected endocarditis caused by Staphylococcus aureus. Withcc's indication expansion, Zyvox's leading position in the methicillin-resistant Staphylococus aureus (MRSA) niche market is set to face a significant challenge. An additional indication in bacteremia and endocarditis caused by Staphylococcus aureus, would help to further drive Cubicin uptake, as well as boosting competition in the MRSA niche market.